Ignite Creation Date:
2024-05-06 @ 9:13 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02932579
Status:
TERMINATED
Last Update Posted:
2022-03-16
First Post:
2016-09-29
Brief Title:
Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
Status:
TERMINATED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was halted permanently due to enrollment and logistic issues
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Opioid analgesics are the most common postoperative pain medications used among dentists in the United StatesAlthough these medications are highly effective in the postoperative dental pain management not all patients optimally benefit from this therapy Many suffer adverse consequences such as nausea emesis and psychomotor impairment and there is a high prevalence of opioid prescription misuse among substance abusers within the dental patient population
The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies typically with significantly less adverse effectsHowever despite these results dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain populationThus new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry Therefore this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar
The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies typically with significantly less adverse effectsHowever despite these results dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain populationThus new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry Therefore this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar
Detailed Description:
To date the use of pharmacogenomic methods in medicine has broadened our understanding of the important role of genes and different phenotypesgenotypes that make each individual unique in pain responses including drug biotransformation transportation and drug-related side effects to name a fewThus recognizing the genetic profile of each individual prior to the prescription of pain medication for postoperative dental pain management will be essential to provide a more effective and safer pain therapyAdditionally we suggest that 80 of the individuals in the general population exhibit a genetic profile that influence a normal pain response to non-opioid pain therapies Hence we postulate that the integration of a pharmacogenomic testing to guide the prescription of ibuprofen and acetaminophen not only could lead to improved clinical postoperative dental pain outcomes but also significantly reduce opioid analgesics prescriptions by dentists
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RSRB00058833 | OTHER | University of Rochester | None |